Genetic testing to study who develops heart failure during breast cancer therapy
Part of Cancer, Skin clinical trials.
This study uses DNA genetic testing to find DNA changes that might explain why some people develop heart failure (CHF) after breast cancer treatment with certain medicines. It may help researchers understand risk and improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are enrolled as a European American or African American participant.
- You have available DNA samples for genetic testing.
- You either developed congestive heart failure (CHF) after completing breast cancer treatment with an anthracycline and bevacizumab, or you completed the full treatment without CHF.
- If you are African American, your heart function likely changed in a way the study defines: a drop in left ventricular ejection fraction (LVEF) below 50% or a drop from your starting level of more than 20 points.
- The study groups people into “cases” (CHF) and “controls” (no CHF) based on the timing and results after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses whole exome DNA testing to look for inherited genetic differences that may explain why some people develop very high blood pressure from bevacizumab during breast cancer treatment. It compares people who did vs. did not develop severe bevacizumab-related hypertension.
This study uses genetic tests on blood DNA to look for differences that may explain why some people develop nerve pain (peripheral neuropathy) from paclitaxel used for breast cancer. It compares people who got significant neuropathy during treatment with people who did not get neuropathy after completing paclitaxel.
This trial studies how a blood test marker (TRPC6) may help predict and prevent heart muscle damage and heart failure related to some breast cancer medicines. You may join if you’re starting or have received treatment that can stress the heart, or if you already have signs of treatment-related heart problems.
This study looks at cancer-related inherited gene changes using blood samples. It may help patients and doctors understand cancer risk and guide treatment planning, especially across different ethnic communities.
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
This study looks for genetic (DNA) clues that may help predict side effects or complications after heart surgery. If you join, your genome information may be used to understand who is at higher risk and why.
Hear when a new Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.